Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · IEX Real-Time Price · USD
445.21
+4.57 (1.04%)
At close: May 17, 2024, 4:00 PM
445.40
+0.19 (0.04%)
After-hours: May 17, 2024, 7:51 PM EDT
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 5,400 employees on December 31, 2023. The number of employees increased by 600 or 12.50% compared to the previous year.
Employees
5,400
Change (1Y)
600
Growth (1Y)
12.50%
Revenue / Employee
$1,886,111
Profits / Employee
$744,333
Market Cap
115.03B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5,400 | 600 | 12.50% |
Dec 31, 2022 | 4,800 | 900 | 23.08% |
Dec 31, 2021 | 3,900 | 500 | 14.71% |
Dec 31, 2020 | 3,400 | 400 | 13.33% |
Dec 31, 2019 | 3,000 | 500 | 20.00% |
Dec 31, 2018 | 2,500 | 200 | 8.70% |
Dec 31, 2017 | 2,300 | 150 | 6.98% |
Dec 31, 2016 | 2,150 | 200 | 10.26% |
Dec 31, 2015 | 1,950 | 120 | 6.56% |
Dec 31, 2014 | 1,830 | 30 | 1.67% |
Dec 31, 2013 | 1,800 | -400 | -18.18% |
Dec 31, 2012 | 2,200 | 200 | 10.00% |
Dec 31, 2011 | 2,000 | 309 | 18.27% |
Dec 31, 2010 | 1,691 | 259 | 18.09% |
Dec 31, 2009 | 1,432 | 99 | 7.43% |
Dec 31, 2008 | 1,333 | 183 | 15.91% |
Dec 31, 2007 | 1,150 | 188 | 19.54% |
Dec 31, 2006 | 962 | 149 | 18.33% |
Dec 31, 2005 | 813 | 77 | 10.46% |
Dec 31, 2004 | 736 | 12 | 1.66% |
Dec 31, 2003 | 724 | -256 | -26.12% |
Dec 31, 2002 | 980 | -20 | -2.00% |
Dec 31, 2001 | 1,000 | 545 | 119.78% |
Dec 31, 2000 | 455 | 102 | 28.90% |
Dec 31, 1999 | 353 | 13 | 3.82% |
Dec 31, 1998 | 340 | 120 | 54.55% |
Dec 31, 1997 | 220 | 42 | 23.60% |
Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elevance Health | 104,900 |
Medtronic | 95,000 |
Pfizer | 88,000 |
Sanofi | 86,088 |
Cigna | 72,500 |
Boston Scientific | 48,000 |
Amgen | 26,700 |
Stryker | 26,700 |
VRTX News
- 3 days ago - Jennifer Schneider Elected to Vertex Board of Directors - Business Wire
- 4 days ago - Vertex Is Writing A New Playbook For Pharma R&D. And It's Working. - Forbes
- 9 days ago - Alpine Immune Sciences Reports First Quarter 2024 Financial Results - Business Wire
- 12 days ago - Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments - Reuters
- 12 days ago - Vertex Reports First Quarter 2024 Financial Results - Business Wire
- 22 days ago - ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN - Business Wire
- 22 days ago - Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older - Business Wire
- 23 days ago - 9 Stocks That Thrive When Interest Rates Are Higher - Barrons